This Article Full Text Full Text (PDF) Supplementary Data, Larsen, et al. Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Larsen, J. E. Articles by Fong, K. M. Search for Related Content PubMed PubMed Citation Articles by Larsen, J. E. Articles by Fong, K. M.

Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma

Authors' Affiliations: ¹ Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia, ² School of Medicine, University of Queensland, and ³ Human Genetics Laboratory, Queensland Institute of Medical Research, Herston, Australia

Requests for reprints: Jill E. Larsen, Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane 4032, Australia. Phone: 61-7-3139-4110; Fax: 61-7-3139-4957; E-mail: Jill_E_Larsen{at}health.qld.gov.au.

Purpose: Improving outcomes for early-stage lung cancer is a major research focus at present because a significant proportion of stage I patients develop recurrent disease within 5 years of curative-intent lung resection. Within tumor stage groups, conventional prognostic indicators currently fail to predict relapse accurately.

Experimental Design: To identify a gene signature predictive of recurrence in primary lung adenocarcinoma, we analyzed gene expression profiles in a training set of 48 node-negative tumors (stage I-II), comparing tumors from cases who remained disease-free for a minimum of 36 months with those from cases whose disease recurred within 18 months of complete resection.

Results: Cox proportional hazards modeling with leave-one-out cross-validation identified a 54-gene signature capable of predicting risk of recurrence in two independent validation cohorts of 55 adenocarcinomas [log-rank P = 0.039; hazard ratio (HR), 2.2; 95% confidence interval (95% CI), 1.1-4.7] and 40 adenocarcinomas (log-rank P = 0.044; HR, 3.3; 95% CI, 1.4-7.9). Kaplan-Meier log-rank analysis found that predicted poor-outcome groups had significantly shorter survival, and furthermore, the signature predicted outcome independently of conventional indicators of tumor stage and node stage. In a subset of earliest stage adenocarcinomas, generally expected to have good outcome, the signature predicted samples with significantly poorer survival.

Conclusions: We describe a 54-gene signature that predicts the risk of recurrent disease independently of tumor stage and which therefore has potential to refine clinical prognosis for patients undergoing resection for primary adenocarcinoma of the lung.

This article has been cited by other articles:

				S. Dubey and C. A. Powell Update in Lung Cancer 2007 Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 941 - 946. [Full Text] [PDF]

				P.-E. Falcoz Invited commentary Ann. Thorac. Surg., January 1, 2008; 85(1): 209 - 210. [Full Text] [PDF]